2006
DOI: 10.1111/j.1463-1326.2006.00586.x
|View full text |Cite
|
Sign up to set email alerts
|

Effects of S 15511, a therapeutic metabolite of the insulin‐sensitizing agent S 15261, in the Zucker Diabetic Fatty rat

Abstract: Treatment with these agents in a genetic model of type 2 diabetes reveals that they all have a transient effect compared to the progressive worsening of vehicle-treated controls. The improvements in glucose metabolism observed with S 15511 are significant, however, suggesting it has more therapeutic activity than the Y 415 metabolite of S 15261. It is associated with less frequent progression to diabetes; i.e. Y 415 exerts a non-significant effect alone and no significant additive effect when combined with S 1… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
5
0

Year Published

2007
2007
2014
2014

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 18 publications
(6 citation statements)
references
References 7 publications
1
5
0
Order By: Relevance
“…Such a decrease in insulin demand following chronic treatment with Poly-GLP-1 is in agreement with previous findings in insulin-resistant obese fa/fa Zucker rats after 6 weeks of exenatide therapy [37]. Both HOMA-IR and QUICKI are the most widely used indices for assessing insulin sensitivity, which derived from fasting glucose and insulin [38][39][40]. Although the values depend on the fasting concentrations of insulin and glucose and thereby estimate mainly hepatic insulin sensitivity [41,42], it provided additional evidence for an insulin-sensitizing effect of Poly-GLP-1 in response to exogenous insulin.…”
Section: Discussionsupporting
confidence: 91%
“…Such a decrease in insulin demand following chronic treatment with Poly-GLP-1 is in agreement with previous findings in insulin-resistant obese fa/fa Zucker rats after 6 weeks of exenatide therapy [37]. Both HOMA-IR and QUICKI are the most widely used indices for assessing insulin sensitivity, which derived from fasting glucose and insulin [38][39][40]. Although the values depend on the fasting concentrations of insulin and glucose and thereby estimate mainly hepatic insulin sensitivity [41,42], it provided additional evidence for an insulin-sensitizing effect of Poly-GLP-1 in response to exogenous insulin.…”
Section: Discussionsupporting
confidence: 91%
“…Homeostasis Model Assessment HOMA-IR was used to estimate insulin resistance [28] and was calculated as [fasting glucose (mM) × fasting insulin (μU/mL)]/22.5.…”
Section: Methodsmentioning
confidence: 99%
“…Homeostasis Model Assesment HOMA-β and HOMA-IR were used to estimate insulin secretion and insulin resistance, respectively [18]. HOMA-β was calculated as [20 x fasting insulin (µU/mL)]/[fasting glucose (mM) -3.5] and HOMA-IR as [fasting glucose (mM) x fasting insulin (µU/mL)]/22.5.…”
Section: Oral Glucose Tolerance Testmentioning
confidence: 99%